Concepts (129)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proto-Oncogene Proteins c-mdm2 | 10 | 2024 | 26 | 5.150 |
Why?
|
| Molecular Targeted Therapy | 8 | 2024 | 35 | 3.450 |
Why?
|
| Antineoplastic Agents | 8 | 2024 | 69 | 3.420 |
Why?
|
| NFATC Transcription Factors | 4 | 2020 | 12 | 2.320 |
Why?
|
| Tumor Suppressor Protein p53 | 7 | 2022 | 29 | 1.950 |
Why?
|
| Neoplasms | 4 | 2024 | 90 | 1.950 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 55 | 1.400 |
Why?
|
| Neuroblastoma | 2 | 2020 | 12 | 1.320 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2019 | 5 | 1.170 |
Why?
|
| Animals | 13 | 2024 | 1711 | 0.820 |
Why?
|
| Signal Transduction | 3 | 2020 | 216 | 0.740 |
Why?
|
| Humans | 15 | 2024 | 4936 | 0.710 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 9 | 0.600 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 16 | 0.600 |
Why?
|
| Mice | 10 | 2022 | 685 | 0.590 |
Why?
|
| Drug Design | 2 | 2020 | 16 | 0.590 |
Why?
|
| Cell Line, Tumor | 7 | 2021 | 160 | 0.570 |
Why?
|
| Triterpenes | 1 | 2018 | 3 | 0.570 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 15 | 0.570 |
Why?
|
| Prostatic Neoplasms | 1 | 2018 | 20 | 0.560 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 96 | 0.470 |
Why?
|
| Melanoma | 2 | 2021 | 28 | 0.330 |
Why?
|
| Protein Binding | 3 | 2022 | 115 | 0.320 |
Why?
|
| Female | 6 | 2020 | 2523 | 0.300 |
Why?
|
| Drug Discovery | 2 | 2020 | 15 | 0.300 |
Why?
|
| Prognosis | 2 | 2019 | 60 | 0.300 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2018 | 14 | 0.290 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2021 | 29 | 0.270 |
Why?
|
| Mice, Nude | 3 | 2020 | 19 | 0.220 |
Why?
|
| Apoptosis | 3 | 2020 | 46 | 0.220 |
Why?
|
| Cell Proliferation | 3 | 2021 | 115 | 0.220 |
Why?
|
| Brain Neoplasms | 2 | 2021 | 25 | 0.200 |
Why?
|
| Male | 3 | 2020 | 2491 | 0.190 |
Why?
|
| Cell Movement | 2 | 2020 | 61 | 0.180 |
Why?
|
| RNA, Small Interfering | 2 | 2021 | 35 | 0.180 |
Why?
|
| Neoplasm Transplantation | 2 | 2019 | 7 | 0.180 |
Why?
|
| Obesity | 2 | 2021 | 115 | 0.180 |
Why?
|
| Uveal Neoplasms | 1 | 2021 | 2 | 0.180 |
Why?
|
| Procollagen-Proline Dioxygenase | 1 | 2021 | 3 | 0.180 |
Why?
|
| Thermogenesis | 1 | 2021 | 1 | 0.170 |
Why?
|
| DNA Modification Methylases | 1 | 2021 | 2 | 0.170 |
Why?
|
| DNA Repair Enzymes | 1 | 2021 | 2 | 0.170 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2021 | 3 | 0.170 |
Why?
|
| Collagen | 1 | 2021 | 34 | 0.170 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2021 | 10 | 0.170 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 15 | 0.170 |
Why?
|
| Glioma | 1 | 2021 | 10 | 0.170 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2020 | 2 | 0.170 |
Why?
|
| Urea | 1 | 2020 | 5 | 0.170 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 27 | 0.170 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2020 | 11 | 0.160 |
Why?
|
| MAP Kinase Signaling System | 1 | 2020 | 6 | 0.160 |
Why?
|
| Medulloblastoma | 1 | 2020 | 2 | 0.160 |
Why?
|
| Glioblastoma | 1 | 2020 | 6 | 0.160 |
Why?
|
| Indoles | 1 | 2020 | 8 | 0.160 |
Why?
|
| Skin Neoplasms | 1 | 2020 | 16 | 0.160 |
Why?
|
| Pyridines | 1 | 2020 | 23 | 0.160 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 225 | 0.160 |
Why?
|
| Nanoparticles | 1 | 2021 | 69 | 0.160 |
Why?
|
| Peptides | 1 | 2020 | 49 | 0.160 |
Why?
|
| Medical Oncology | 1 | 2019 | 2 | 0.160 |
Why?
|
| Sjogren's Syndrome | 1 | 2019 | 2 | 0.160 |
Why?
|
| Glomerulonephritis | 1 | 2019 | 6 | 0.160 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2019 | 4 | 0.150 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 6 | 0.150 |
Why?
|
| Lupus Nephritis | 1 | 2019 | 6 | 0.150 |
Why?
|
| Neurodegenerative Diseases | 1 | 2019 | 7 | 0.150 |
Why?
|
| Heart Diseases | 1 | 2019 | 11 | 0.150 |
Why?
|
| Kidney Diseases | 1 | 2019 | 10 | 0.150 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2019 | 1 | 0.150 |
Why?
|
| Hep G2 Cells | 1 | 2019 | 5 | 0.150 |
Why?
|
| Neoplasm Invasiveness | 1 | 2019 | 9 | 0.150 |
Why?
|
| Neoplasms, Experimental | 1 | 2019 | 5 | 0.150 |
Why?
|
| Ubiquitination | 1 | 2019 | 7 | 0.150 |
Why?
|
| Biomarkers | 1 | 2019 | 81 | 0.150 |
Why?
|
| Inflammation | 1 | 2019 | 57 | 0.150 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 17 | 0.150 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 32 | 0.150 |
Why?
|
| Fluorescent Dyes | 1 | 2019 | 32 | 0.150 |
Why?
|
| Models, Molecular | 1 | 2019 | 82 | 0.150 |
Why?
|
| Deoxycytidine | 1 | 2018 | 5 | 0.140 |
Why?
|
| Calcineurin | 1 | 2018 | 11 | 0.140 |
Why?
|
| Dementia | 1 | 2019 | 50 | 0.140 |
Why?
|
| RING Finger Domains | 1 | 2018 | 2 | 0.140 |
Why?
|
| Proteolysis | 1 | 2018 | 7 | 0.140 |
Why?
|
| Nuclear Proteins | 1 | 2018 | 14 | 0.140 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2018 | 9 | 0.140 |
Why?
|
| Rats | 1 | 2019 | 241 | 0.140 |
Why?
|
| Mice, Transgenic | 1 | 2018 | 47 | 0.140 |
Why?
|
| Cell Cycle Proteins | 1 | 2018 | 19 | 0.140 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 8 | 0.130 |
Why?
|
| Child | 1 | 2020 | 627 | 0.130 |
Why?
|
| Middle Aged | 1 | 2019 | 967 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 184 | 0.080 |
Why?
|
| Ubiquitin | 1 | 2022 | 6 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2022 | 6 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 1 | 2022 | 30 | 0.050 |
Why?
|
| Prolyl Hydroxylases | 1 | 2021 | 2 | 0.040 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 6 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 12 | 0.040 |
Why?
|
| Adipose Tissue, White | 1 | 2021 | 6 | 0.040 |
Why?
|
| Stromal Cells | 1 | 2021 | 6 | 0.040 |
Why?
|
| CCCTC-Binding Factor | 1 | 2021 | 2 | 0.040 |
Why?
|
| Nuclear Respiratory Factor 1 | 1 | 2021 | 3 | 0.040 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2021 | 4 | 0.040 |
Why?
|
| RNA, Untranslated | 1 | 2021 | 6 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2021 | 27 | 0.040 |
Why?
|
| Genomics | 1 | 2021 | 38 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2021 | 27 | 0.040 |
Why?
|
| MAP Kinase Kinase 2 | 1 | 2020 | 2 | 0.040 |
Why?
|
| Nedd4 Ubiquitin Protein Ligases | 1 | 2020 | 2 | 0.040 |
Why?
|
| Macaca fascicularis | 1 | 2020 | 3 | 0.040 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2020 | 3 | 0.040 |
Why?
|
| Sp1 Transcription Factor | 1 | 2020 | 2 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2020 | 2 | 0.040 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2020 | 2 | 0.040 |
Why?
|
| Heat-Shock Proteins | 1 | 2020 | 5 | 0.040 |
Why?
|
| Mice, Inbred NOD | 1 | 2020 | 5 | 0.040 |
Why?
|
| Molecular Docking Simulation | 1 | 2020 | 27 | 0.040 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2020 | 6 | 0.040 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2020 | 4 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2020 | 44 | 0.040 |
Why?
|
| Membrane Transport Proteins | 1 | 2020 | 12 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2020 | 26 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 15 | 0.040 |
Why?
|
| A549 Cells | 1 | 2019 | 3 | 0.040 |
Why?
|
| Heterografts | 1 | 2019 | 8 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 1 | 2019 | 24 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2019 | 39 | 0.040 |
Why?
|